Johnson & Johnson Ortho Evra Suits Put Preemption Front And Center – Again
This article was originally published in The Pink Sheet Daily
Executive Summary
Plaintiffs cite J&J’s manufacturing negligence in response to the firm’s motion to dismiss product liability suits related to the patch.
You may also be interested in...
Public Citizen Demands Removal of J&J’s Ortho Evra Patch From Marketplace
Petition to FDA claims drug exposes women to 60 percent more estrogen and may increase the risk of blood clots two-fold.
Public Citizen Demands Removal of J&J’s Ortho Evra Patch From Marketplace
Petition to FDA claims drug exposes women to 60 percent more estrogen and may increase the risk of blood clots two-fold.
Supreme Court Reaches Tie Vote in FDA Preemption Case
Court lets lower court ruling against Warner-Lambert stand but does not answer question regarding federal preemption in product liability.